300765.SZ
石药创新
SZSE · Consumer Defensive · C 制造业 · CN
CNY 45.24
−7.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.4B | 2.2B | 2.0B | 2.5B | 2.6B |
| Cost of Revenue | 1.4B | 1.3B | 1.1B | 1.4B | 1.5B |
| Gross Profit | 913.0M | 827.9M | 831.4M | 1.2B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 1.1B | 1.0B | 842.2M | 671.4M | 46.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 107.0M | 96.2M | 82.2M | 94.2M | 69.5M |
| Selling & Marketing Expense | 286.0M | 281.3M | 154.2M | 210.5M | 244.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.5B | 1.4B | 1.1B | 932.7M | 293.8M |
| Cost and Expenses | 3.0B | 2.8B | 2.2B | 2.3B | 1.8B |
| Operating Income (EBIT) | (537.3M) | (545.4M) | (218.3M) | 261.5M | 855.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (543.0M) | (551.5M) | (221.3M) | 262.1M | 851.4M |
| Income Tax Expense | 53.8M | 57.8M | 81.9M | 136.5M | 124.8M |
| Bottom Line | |||||
| Net Income | (308.1M) | (241.1M) | 53.7M | 434.4M | 726.3M |
| Earnings from Cont. Ops | (596.8M) | (609.3M) | (303.2M) | 125.7M | 726.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (308.1M) | (241.1M) | 53.7M | 434.4M | 726.3M |
| Per Share | |||||
| Basic EPS | (CN¥0.22) | (CN¥0.17) | CN¥0.04 | CN¥0.31 | CN¥0.65 |
| Diluted EPS | (CN¥0.22) | (CN¥0.17) | CN¥0.04 | CN¥0.31 | CN¥0.65 |
| Revenue Per Share | CN¥1.69 | CN¥1.55 | CN¥1.42 | CN¥1.82 | CN¥2.36 |
| Shares | |||||
| Basic Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.4B | 1.1B |
| Diluted Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.4B | 1.1B |
| Profitability Metrics | |||||
| EBITDA | — | (323.2M) | (2.0M) | 416.3M | 927.7M |
| D&A | — | 222.3M | 216.3M | 154.8M | 72.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026